HADS (Hospital Anxiety and Depression Scale)

OTHER4 trials

Sponsors

University of Technology Sydney, Cardiocentro Ticino, Centre Hospitalier Universitaire de Saint Etienne, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

Anxiety PostoperativeDepressionDepression, AnxietyGeneralized AnxietyIntrospective & Anxiety-Prone PatientNSCLCPostoperative DeliriumRefractory breathlessness in patients with a chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) Respiratory Chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD)

Phase 3

BETTER-B (Aus): Better treatments for refractory breathlessness

RecruitingISRCTN15751764

University of Technology SydneyRefractory breathlessness in patients with a chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) Respiratory Chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD)

Start: 2021-05-18Target: 50Updated: 2024-09-30

Unknown Phase

Predictors of Postoperative Delirium After Transcatheter Aortic Valve Implantation

CompletedNCT02585128

Cardiocentro TicinoPostoperative Delirium

Start: 2015-09-30End: 2021-01-31Updated: 2024-04-18

Validation of a Rapid Screening Tool for Anxiety-depressive Disorders in Children, Adolescents and Young Adults Treated in Oncology. Multicenter Study.

RecruitingNCT07117058

Centre Hospitalier Universitaire de Saint EtienneDepression, Anxiety, Generalized Anxiety, Introspective & Anxiety-Prone Patient +1

Start: 2025-03-18End: 2027-09-01Target: 545Updated: 2026-03-30

Influence of a PSychological Intensive Support Program for Lung Cancer Patients ON Post-operative Outcomes.

Not yet recruitingNCT07260227

Fondazione Policlinico Universitario Agostino Gemelli IRCCSAnxiety Postoperative, Depression, NSCLC

Start: 2025-12-01End: 2027-04-30Target: 138Updated: 2025-12-03

Related Papers

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial.

2024-09-0910 citations